ELICIO THERAPEUTICS INC (ELTX)
Health Care · biotechnology · NASDAQ
Elicio Therapeutics is developing lymph node-targeted, off-the-shelf immunotherapies for mKRAS-driven solid tumors using its proprietary AMP technology platform.
What ELICIO THERAPEUTICS INC does
Elicio Therapeutics is a clinical-stage biotechnology company developing immunotherapies for cancer, including pancreatic, colorectal, and lung cancers. Its proprietary Amphiphile (AMP) technology platform is designed to target payloads to lymph nodes to generate robust cancer-specific T cell responses. The company's lead candidate, ELI-002, is an off-the-shelf therapeutic vaccine targeting mutant KRAS-driven tumors.
Recent developments
In June 2026, the company reported that its Phase 2 AMPLIFY-7P trial for ELI-002 7P in adjuvant PDAC did not meet its primary disease-free survival endpoint, though it showed early treatment benefit in subgroups. Elicio plans to initiate a Phase 1 study of ELI-002 7P in combination with a RAS small molecule inhibitor and/or anti-PD-1 inhibitor in metastatic PDAC in Q4 2026. In July 2026, the company raised $15 million in a registered direct offering to extend its cash runway into Q1 2027.
From ELICIO THERAPEUTICS INC's filing of 2026-08-13.
Themes: cancer immunotherapy, mKRAS-driven cancers, vaccine technology, lymph node-targeted delivery, oncology
Fundamentals
- Price$1.81 as of 2026-10-08 close
- Market cap$35M as of 2026-05-08 (share count; price 2026-10-08)
- 1-year return-82.8% 2025-10-08 close $10.52 → 2026-10-08 close $1.81
- P/En/a negative earnings
- Net margin-1225.9% FY2022, SEC XBRL
- ROE-2418.8% FY2025, SEC XBRL
- Debt / equity5.75 as of 2026-09-03
- Revenue growth (YoY)-91.9% as of 2026-09-03
- Revenue CAGR (3y)-10.6% SEC XBRL
- Beta0.51 as of 2026-09-03
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How ELTX compares in its sector
- net profit marginbottom 10% 430 covered Health Care peers, as of 2026-09-03
- operating marginbottom 25% 417 covered Health Care peers, as of 2026-09-03
- return on equitybottom 10% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ELICIO THERAPEUTICS INC looks technically
ELICIO THERAPEUTICS INC (ELTX) is trading 74.8% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 70 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 35, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 28, in oversold territory (below 30). It made a new 20-day low about 17 trading days ago. It is 87.9% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 2% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 74.8% below its 200-day average, the long-term trend line — a long-term downtrend | -74.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $2.48 | $2.48 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $7.17 | $7.17 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 22 calendar days ago — the swings before that are what the structure reading is measured on | 22 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 1.705. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a five-part sequence in leg 4. | possible three-wave downward correction, complete (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 70 trading days ago — a "death cross", a bearish long-term signal | 70 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 35, with sellers in control | 35.2 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 28, in oversold territory (below 30) | 28.2 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($1.74 to $2.02) — its "stochastic" reading is 25 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 25.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 12 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $14.93 | $14.93 |
|---|---|---|
| From the 52-week high | it is 87.9% below its 52-week high (its highest price of the past year) | -87.9% |
| Above the 52-week low | it is 6.2% above its 52-week low (its lowest price of the past year) | +6.2% |
| Below the 52-week high | it is 87.9% below its highest point of the past year | 87.9% |
| Since a 20-day breakout | it made a new 20-day low about 17 trading days ago | 17 sessions |
| Since a 55-day breakout | it made a new 55-day low about 17 trading days ago | 17 sessions |
| All-time high | its highest closing price on record is $263.00 (set on 2021-02-19) | $263.00 |
| Given back of the 52-week move | over the past year its closes ranged ($1.77 to $14.85), and it has recovered essentially none of its fall from last year’s high — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $9.85 to $10.27. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.3% |
| From the all-time high | it is 99.3% below its all-time high | -99.3% |
| Nearest price level | it is trading 155.5% below a resistance level at $4.63 — a price it turned at twice since 2024-12-06, most recently on 2025-04-09. Since 2024-10-08 it has 0 such levels below the current price and 15 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +155.5% |
| All-time low | its lowest closing price on record is $1.71 (set on 2026-09-16) | $1.71 |
| Above the all-time low | it is 6.2% above its all-time low | +6.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 2% of the past ~6 months), which often precedes a bigger move | 2nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1356 between its high and its low — about 7.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1356 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $1.76 and $2.02 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $1.76 – $1.89 – $2.02 |
| Typical daily range (% of price) | its price moves about 7.5% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.5% |
| Stretch from the 200-day average | it is trading 39.5 daily ranges below its 200-day average price (74.8% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 39.5 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.78× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|---|---|
| Since a bullish engulfing | 5 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 5 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Gap filled | a 4.5% gap down opened on 2026-09-16 has been "filled" 14 sessions ago — price traded back through the level the gap left behind, and it took 2 sessions to close | 14 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 3 sessions in a row, a -5.73% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 3 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 24.0 percentage points (the stock lost 23.0% while the market gained 1.0%) | -24.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 52.0 percentage points (the stock lost 48.1% while the market gained 3.8%) | -52.0% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 100.5 percentage points (the stock lost 83.0% while the market gained 17.5%) | -100.5% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 97.8 percentage points (the stock lost 82.8% while the market gained 15.0%) | -97.8% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: its RSI momentum gauge is oversold (a beaten-down reading), MACD momentum is positive — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 38% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 58.9% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -37.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 61% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $4.67 — a volume-weighted average of daily closes over 188 sessions, not a true tick-by-tick VWAP. | -61.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 21% below the average price paid since it last reported on 2026-08-13 (its 10-Q), so the typical buyer over that stretch is under water. That average is $2.29 — a volume-weighted average of daily closes over 40 sessions, not a true tick-by-tick VWAP. | -21.1% |
Price levels it has turned at before
ELTX last closed at $1.81 on 2026-10-08. Since 2024-10-08 it has turned at 0 prices below its last close and 15 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $4.63 | Resistance | 155.5% above the last close | turned there twice · 2024-12-06 to 2025-04-09 |
| $4.70 | Resistance | 159.7% above the last close | turned there twice · 2024-12-20 to 2025-04-29 |
| $4.86 | Resistance | 168.5% above the last close | turned there twice · 2024-12-31 to 2025-05-07 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $1.71.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
Alternate reading: The same swings also read as a five-part sequence in leg 4, which fails on a close above $2.72.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Oversold (14-day RSI below 30) · Pulled back from the 12-month high · in a Bollinger Band volatility squeeze · lagging the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.50 mean, 1=Strong Buy…5=Strong Sell) — 3 analysts
- Mean price target$13.67 range $8.00 – $23.00; median $10.00
Analyst estimates, as of 2026-10-08. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ELTX
- Consensus EPS estimate-$0.43 next reporting period, as of 2026-10-08
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company is unprofitable and has a limited cash runway into Q1 2027, requiring additional financing to continue operations and fund clinical trials.","Clinical trial failures, such as the primary endpoint miss in the Phase 2 AMPLIFY-7P study, present significant risks to the development of lead candidates.","The company is at an early stage of clinical development with no approved commercial products, and its success depends on the safety and efficacy of its proprietary AMP technology."]
What changed in the latest 10-Q
AI-assisted comparison of ELTX's 10-Q filed 2026-08-13 against the prior one filed 2026-05-11.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-13) states the Phase 2 AMPLIFY-7P trial did not meet its pre-specified primary DFS endpoint in the intent-to-treat population.
- Newer filing (2026-08-13) states DFS analysis at three months and six months showed early treatment benefit and a stronger treatment effect in subsets of the patient population.
- Newer filing (2026-08-13) states ELI-002 7P demonstrated a favorable safety profile.
- Newer filing (2026-08-13) states the company is continuing to evaluate pre-specified subgroups including the R0 resected population and intends to further refine its development strategy for the planned Phase 3 study.
- Newer filing (2026-08-13) adds a new 'Recent Developments' section titled 'AMPLIFY-7P Phase 2 Topline Results'.
- Newer filing (2026-08-13) states the AMPLIFY-7P study enrolled 144 patients across 24 U.S. sites.
- Newer filing (2026-08-13) states the study evaluated ELI-002 7P versus observation in patients with resected Stage I-III mKRAS-driven PDAC who had completed surgery and standard locoregional therapy and were radiographically free of disease at enrollment.
- Newer filing (2026-08-13) states DFS analyses showed an approximately 14% absolute DFS benefit during active treatment at both three and six months, with treatment-arm separation persisting through nine months.
- Newer filing (2026-08-13) states a higher proportion of patients with other adverse prognostic factors were included in the ELI-002 7P arm relative to the comparator standard of care arm.
- Newer filing (2026-08-13) states subgroup analyses intended to account for these imbalances showed a significant DFS improvement.
- Newer filing (2026-08-13) states there are currently no approved therapies following locoregional treatment.
- Newer filing (2026-08-13) states the study demonstrated a strong association between mKRAS-specific immune responses and clinical outcomes (HR 0.22, p<0.0001, n=90).
- Newer filing (2026-08-13) states ELI-002 7P demonstrated a favorable safety profile with no treatment-related discontinuations or deaths.
- Newer filing (2026-08-13) states the company may include stratification and/or exclusion for adverse baseline factors in its Phase 3 development strategy.
- Newer filing (2026-08-13) states the company intends to initiate a Phase 1 study evaluating ELI-002 7P in combination with a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor in recurrent and treatment-naive metastatic mKRAS PDAC, based on preliminary post-study observations suggesting ELI-002 7P-induced immune responses may enhance sensitivity to checkpoint inhibition.
- Newer filing (2026-08-13) states the company may seek to expand ELI-002 7P to other indications subject to financing.
- Removed:
- Older filing (2026-05-11) states ELI-002 7P was currently being evaluated in a Phase 2 study; the newer filing refers to it being evaluated in a Phase 1/2 study, AMPLIFY-7P.
- Older filing (2026-05-11) states that in August 2025 the IDMC recommended the AMPLIFY-7P trial continue to final analysis without modifications and confirmed favorable safety profile; this language is not present in the newer filing.
- Older filing (2026-05-11) states the final disease-free survival analysis was anticipated mid-year 2026; this statement is not present in the newer filing.
- Older filing (2026-05-11) states 'In the future, we plan to expand ELI-002 7P to other indications including mKRAS positive lung cancer and other mKRAS positive cancers' without the 'subject to financing' qualifier included in the newer filing.
- Older filing (2026-05-11) includes a statement that the company believes each immunotherapy product candidate, if approved, has the potential to reduce the risk of recurrence of tumors carrying specific oncogenic driver mutations; the newer filing adds mention of decreasing tumor burden.
- Older filing (2026-05-11) includes paragraphs discussing financing history (aggregate net proceeds of $227.5 million), net loss figures ($11.8 million and $11.2 million for the three months ended March 31, 2026 and 2025), accumulated deficit of $245.5 million, cash and cash equivalents of $14.9 million as of March 31, 2026, and substantial doubt about going concern; these paragraphs are not present in the newer MD&A text provided.
- Reworded:
- Older filing (2026-05-11) describes the company as 'a clinical-stage biotechnology company advancing novel immunotherapies'; the newer filing (2026-08-13) describes it as 'a clinical-stage biotechnology company developing next-generation immunotherapies'.
- Older filing (2026-05-11) states 'mutant Kirsten rat sarcoma viral oncogene homolog' was abbreviated as "mKRAS" in the overview; the newer filing (2026-08-13) refers to "mKRAS"-positive cancers without repeating the full expansion in that location, though both refer to the same term.
- Older filing (2026-05-11) states the company believes each immunotherapy product candidate, if approved, has the potential to 'reduce the risk of recurrence of tumors'; the newer filing (2026-08-13) states each product candidate has the potential to 'decrease tumor burden or reduce the risk of recurrence of tumors'.
- Older filing (2026-05-11) states 'Our preclinical pipeline includes the lymph node targeted immunotherapies ELI-007... and ELI-008'; the newer filing (2026-08-13) writes 'lymph node-targeted immunotherapies' with a hyphen.
- Older filing (2026-05-11) describes ELI-002 7P as 'the lymph node targeted cancer immunotherapy'; the newer filing (2026-08-13) describes it as 'the lymph node-targeted cancer immunotherapy' with a hyphen.
- Older filing (2026-05-11) refers to 'mKRAS positive' cancers; the newer filing (2026-08-13) uses 'mKRAS-positive' with a hyphen.
- Older filing (2026-05-11) includes the IDMC interim review details immediately following the ELI-002 7P description; the newer filing (2026-08-13) replaces that content with the June 2026 Phase 2 results in the same location.
- Notes:
- The provided MD&A text from the newer filing ends mid-sentence after 'adverse baseline factors' and may be incomplete; the older filing text ends after 'financial st' and also appears truncated.
- The comparison covers only the provided MD&A excerpts and not the full MD&A sections from either filing.
Risk Factors
- Added:
- Newer filing states 'other than as follows' after 'no material changes in our risk factors from those described in the Form 10-K,' indicating additional risk factor disclosure follows.
- Newer filing adds a 'Risks Related to the Development of our Product Candidates' heading.
- Newer filing adds a risk factor titled 'Our product candidates are at an early stage of clinical development and may not be successfully developed or commercialized.'
- Newer filing adds disclosure that in June 2026 the company reported topline results from the randomized Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with adjuvant mKRAS-driven PDAC.
- Newer filing adds that AMPLIFY-7P did not meet its pre-specified primary DFS endpoint in the intent-to-treat population; however, DFS analysis at three and six months showed early treatment benefit and a stronger treatment effect in subsets of the patient population.
- Newer filing adds that the company continues to evaluate pre-specified subgroups, including the R0 resected population, and intends to use such results to further refine its development strategy for a planned Phase 3 study in adjuvant PDAC.
- Newer filing adds that based on preliminary post-study observations suggesting ELI-002 7P-induced immune responses may enhance sensitivity to checkpoint inhibition, the company announced its intention to initiate a Phase 1 study evaluating ELI-002 7P in combination with a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor in metastatic mKRAS pancreatic cancer, anticipated to initiate in the fourth quarter of 2026.
- Newer filing adds that the planned Phase 1 combination study in metastatic PDAC is the company's near-term priority, while the planned Phase 3 registrational trial in adjuvant PDAC is not expected to commence until the company completes an additional capital raise.
- Newer filing adds that the pursuit of multiple clinical programs at different stages of development and treatment settings creates distinct risks and uncertainties at each stage.
- Newer filing adds that results from AMPLIFY-201 and AMPLIFY-7P studies may not be predictive of outcomes in the planned Phase 1 combination study or Phase 3 trial due to differences in study design, patient populations, treatment settings, and combination regimens.
- Newer filing adds historical details including April 2023 completion of enrollment for AMPLIFY-201 trial for ELI-002 2P targeting KRAS gene mutations, October 2023 completion of AMPLIFY-7P Phase 1 enrollment, January 2024 initiation of AMPLIFY-7P Phase 2 enrollment, December 2024 completion of AMPLIFY-7P Phase 2 enrollment, August 2025 positive IDMC recommendation, and June 2026 topline results.
- Newer filing adds that all other product candidates are in preclinical development and will require substantial further capital expenditures, development, testing, and regulatory approval prior to commercialization.
- Newer filing adds a risk factor titled 'Our planned Phase 1 study evaluating ELI-002 7P in combination with a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor in metastatic mKRAS pancreatic cancer may present additional safety risks, and the combination of multiple agents may result in unexpected adverse events or tolerability issues.'
- Newer filing adds that the planned Phase 1 study will be in treatment-naive and recurrent metastatic mKRAS pancreatic cancer and follows preliminary post-study observations in a small number of patients from the completed Phase 2 AMPLIFY-7P study.
- Newer filing adds that the company has observed a favorable safety profile for ELI-002 7P as a monotherapy (text appears truncated).
- Reworded:
- Older filing states 'There have been no material changes in our risk factors from those described in the Form 10-K.' with no additional risk factor text. Newer filing modifies this to 'There have been no material changes in our risk factors from those described in the Form 10-K, other than as follows.' and then provides additional risk factor disclosure.
- Notes:
- The newer filing text appears truncated at the end, mid-sentence in the section about the planned Phase 1 study and ELI-002 7P monotherapy safety profile, so changes after the truncation point cannot be assessed.
- The older filing section labeled 'Risk Factors' includes items that appear to be from other parts of the Form 10-Q (Items 2-6, exhibits, signatures), so the older filing may not contain the risk factor text in the same manner as the newer filing.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for ELTX — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding ELTX as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 1,243,949
- Reported value $4,863,840
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 3 increased, 0 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about ELTX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
ELTX had 1,666,426 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
ELTX had 8.73% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.44 days to cover at the same settlement.
- Reported short interest (shares) 1,666,426
- Short interest (% of shares outstanding) 8.73%
- Prior settlement (shares) 1,584,267
- Reported change 5.19%
- Days to cover (reported) 4.44
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Moderna (MRNA)
- BioNTech (BNTX)
- Gritstone bio (GRTS)
- Agenus (AGEN)
- Neon Therapeutics (BNTX)
- Vaccitech (VACC)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ELTX vs…
ELICIO THERAPEUTICS INC is found in…
Frequently asked questions
What does ELICIO THERAPEUTICS INC (ELTX) do?
Elicio Therapeutics is a clinical-stage biotechnology company developing immunotherapies for cancer, including pancreatic, colorectal, and lung cancers. Its proprietary Amphiphile (AMP) technology platform is designed to target payloads to lymph nodes to generate robust cancer-specific T cell responses. The company's lead candidate, ELI-002, is an off-the-shelf therapeutic vaccine targeting mutant KRAS-driven tumors.
What sector is ELICIO THERAPEUTICS INC (ELTX) in?
ELICIO THERAPEUTICS INC (ELTX) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are ELICIO THERAPEUTICS INC's (ELTX) competitors?
Notable peers of ELICIO THERAPEUTICS INC (ELTX) include Moderna, BioNTech, Gritstone bio, Agenus and Neon Therapeutics. This peer set is informational only — not financial advice.
Is ELICIO THERAPEUTICS INC (ELTX) overbought or oversold right now?
ELICIO THERAPEUTICS INC (ELTX) is currently in oversold territory (its 14-day RSI is 28, below 30) (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ELTX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.